A plethora of studies have demonstrated that PTPN2 and PTP1B (PTPN2/N1) contribute to the aggressiveness of cancer by modulating key pathways and molecules such as PTEN, Src activation, and the PKM2/AMPK/mTOC1 pathway [15,16]. The gene discussed is PTEN; the disease is cancer.